Company ProfilePremium

Neuren Pharmaceuticals Limited

Company Profile Analysis

Ticker: NEU.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Neuren Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

2001

Neuren Pharmaceuticals Limited logo

Neuren Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Neuren Pharmaceuticals Limited Overview

Neuren Pharmaceuticals is a New Zealand-incorporated, Melbourne-headquartered biopharmaceutical company that discovers and develops orally administered synthetic analogues of naturally occurring peptides derived from insulin-like growth factor 1 (IGF-1), targeting serious neurodevelopmental disorders of early childhood. Its first drug, trofinetide, is the only approved therapy for Rett syndrome in the US, EU, Canada and Israel. Acadia Pharmaceuticals markets it under an exclusive worldwide licence as DAYBUE®, DAYBUE® STIX and, in the EU, DAYBU®. In return Neuren receives tiered royalties and milestones, which converted the company from a cash-consuming developer into a profitable, debt-free royalty business with A$287m of cash. That cash flow now funds the company's second asset, NNZ-2591 (ercanetide), which is in the first-ever Phase 3 trial in Phelan-McDermid syndrome and in development for Pitt Hopkins syndrome, Angelman syndrome and hypoxic-ischemic encephalopathy. In 2026 Neuren introduced a semi-annual, fully franked dividend, which makes it a rare dividend-paying ASX biotech.


Company's own description

In its 2026 ASX announcements, Neuren describes itself as "developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options," with therapies that "target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides" (About Neuren boilerplate, H1 2026 announcement, 26 Aug 2026).

Independent characterisation

Neuren is best understood as a hybrid royalty vehicle and clinical-stage developer. It has two economic engines.

  1. Trofinetide royalty and milestone stream (out-licensed, commercial). Neuren does not manufacture, sell or distribute trofinetide. Acadia holds an exclusive worldwide licence: North America since 2018, extended to the rest of the world in 2023. Acadia funds all development, regulatory, manufacturing and commercial activity. Neuren's economics consist of:

    • North America: tiered, escalating double-digit royalties on net sales. The first tier is 10%, which was the effective rate in 2023 according to the Q4 2023 Activity Report. Sales milestones are payable when calendar-year North American net sales cross escalating thresholds. The first, US$50m at the US$250m threshold, was earned in FY2024. The next is US$50m when North American net sales exceed US$500m in a calendar year (H1 2026 announcement).

    • Europe: US$35m on first commercial sale, up to US$170m of sales milestones, and tiered royalties from mid-teens to low-20s percent of European net sales (H1 2026 announcement).

    • Japan: US$15m on first commercial sale for Rett, US$4m on first commercial sale for a second indication, up to US$110m of sales milestones, and mid-teens to low-20s percent royalties (H1 2026 announcement; 24 Apr 2024 announcement).

    • Other ex-North America territories: royalties and milestones under the 2023 global licence expansion, on terms summarised in Neuren's licence disclosures.

    • Fragile X: a further US$55m milestone if Acadia develops trofinetide for Fragile X syndrome (Q4 2023 Activity Report).

  2. NNZ-2591 (ercanetide) development (wholly owned, clinical). Neuren keeps worldwide rights to NNZ-2591 in all indications except Rett syndrome and Fragile X syndrome, which are licensed to Acadia. Neuren funds and runs NNZ-2591 development itself. It is the main source of the company's long-term optionality, including potential Rare Pediatric Disease Priority Review Vouchers (PRVs), which Neuren would own 100% of.

Revenue model mix

Revenue typeNatureFY2025 status
RoyaltiesRecurring, quarterly, US$-denominated, tied to DAYBUE net salesA$64.6m. This is about 76% of total revenue from ordinary activities (derived from the FY2025 Appendix 4E).
Milestones (development, first sale, sales thresholds)Episodic, large, US$-denominatedNil in FY2025. A$80.5m in FY2024; A$59.4m in FY2023.
Upfront licence feesOne-offA$146m in FY2023 (global licence expansion)
PRV proceeds shareOne-offA$76.5m in FY2024 (Neuren's one-third share of Acadia's PRV sale)
Finance incomeInterest on cash and term depositsA$5.6m in H1 2026
Product sales / services / subscriptions—Not applicable

Value-chain position, customers and end-markets

Value-chain position: Upstream. Neuren covers discovery, early and late clinical development (for NNZ-2591), regulatory strategy and IP ownership. For trofinetide it sits entirely upstream of its licensee's commercial operations.

Customer: Effectively one, Acadia Pharmaceuticals (Nasdaq: ACAD), which is the sole source of royalty and milestone revenue. End users are patients with Rett syndrome and their prescribing physicians, accessed through Acadia.

End-markets: Rare paediatric neurodevelopmental disorders: Rett syndrome (commercial), Phelan-McDermid syndrome (Phase 3), Pitt Hopkins syndrome (end of Phase 2), Angelman syndrome (Phase 2 completed), and hypoxic-ischemic encephalopathy (pre-IND). Fragile X syndrome is licensed to Acadia.

Strategy

Stated strategy

Neuren's strategy has three pillars, set out consistently since 2024 ("three key drivers adding value", ASX 24 Apr 2024):

  1. Realise Neuren's share of trofinetide value in the US through royalties and sales milestones.

  2. Realise Neuren's share of trofinetide value outside North America through the Acadia global licence (Europe, Japan and other markets).

  3. Maximise the value of NNZ-2591 as a multiple-indication platform, with global rights kept by Neuren.

In 2026 management added a fourth explicit theme: optimising total shareholder return through ongoing fully franked dividends, while funding all NNZ-2591 development internally. The CEO described this as the "enviable position" of funding development "aiming for significant capital appreciation, as well as optimis[ing] total shareholder return" (H1 2026 announcement).

Initiatives in the last 24 months

InitiativeDateDetail
Koala Phase 3 (PMS)Initiated 2025; first dosing Feb 2026First-ever Phase 3 in PMS; about 160 children; US$80–90m program budget
PTHS regulatory pathEarly 2026 to Oct 2026Alternative trial designs and endpoint methodologies assessed; Type B meeting with FDA in late Oct 2026
HIE programAdded H1 2025Pre-IND engagement Feb 2026; juvenile animal study; IND expected H1 2027
SYNGAP1 programAdded 2025Early stage
Capital management: buybacksDec 2024 to H1 2026A$50m program completed H1 2025 (average A$12.27); further on-market buybacks of A$3.9m in H1 2026
Dividend policyAug 2026Semi-annual payout of 70–100% of the Available Pool, fully franked to the maximum extent possible
Community and diagnosis initiatives2025–2026Presenting Sponsor of the PMSF Family Conference (Jul 2026); supported a prevalence study in Autism Research estimating PMS at 1 in 7,300
PRV optionalityOngoingUS PRV program reauthorised to Sep 2029. Neuren holds Rare Pediatric Disease designations in PMS, PTHS and AS and would own 100% of any voucher. A recent industry sale was US$215m (Jul 2026).

ESG and cost programs: No formal ESG targets or cost-reduction programs are disclosed. Corporate costs are deliberately small (A$6.2m in FY2025; A$6.6m estimated for FY2026).

Guidance

ItemGuidanceSource
FY2026 royalty incomeUS$52.6–56.2m (rounded US$53–56m), about A$75.1–80.3m at 0.70. Originally A$70–77m (Feb 2026).H1 2026 announcement
FY2026 Available PoolA$48.0–51.6mH1 2026 announcement
FY2026 corporate & admin costsAbout A$6.6mH1 2026 announcement
PMS program total costUS$80–90mH1 2026 announcement
Acadia FY2026 DAYBUE net salesUS$480–510mAcadia, Aug 2026
Acadia 2028 DAYBUE targetUS$700m global net salesAcadia, reaffirmed Aug 2026
JapanTop-line Sep–Nov 2026; submission 20275 Aug 2026 announcement

Neuren does not give medium-term revenue or EPS targets of its own.

Products & Services

Commercial product (out-licensed)

AttributeTrofinetide: DAYBUE® oral solution
MoleculeTrofinetide (formerly NNZ-2566), a synthetic analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1
IndicationRett syndrome. US: adults and paediatric patients aged 2 and over.
ApprovalsUS FDA (Mar 2023); Health Canada; Israel; European Commission (24 Aug 2026, as DAYBU, ages 5 and over)
LaunchUS, 17 Apr 2023 (Acadia). Germany anticipated early Q4 2026.
CommercialiserAcadia Pharmaceuticals (exclusive worldwide licence)
Net sales (Acadia, US$)2023: 177.2m; 2024: 348.4m; 2025: 391.4m; H1 2026: 226m (global)
2026 guidanceUS$480–510m global net sales (raised from US$460–490m in Aug 2026)
Long-term targetAcadia reaffirmed a target of US$700m global net sales in 2028
Neuren economicsTiered North American royalty starting at 10%; North American sales milestones; ex-North America royalties of mid-teens to low-20s percent; Europe and Japan milestones (see Section 2.2)
PricingSet by Acadia; not disclosed by Neuren
AttributeTrofinetide: DAYBUE® STIX
DescriptionNew powder (sachet) formulation of trofinetide, designed to improve ease of administration and tolerability management
LaunchLimited US launch in Q1 2026 at Rett syndrome Centers of Excellence (over 250 prescriptions, about 30% for new or returning patients); broad US availability from early Q2 2026
AdoptionBy 30 Jun 2026, 40% of US DAYBUE patients were on STIX. About 45% of STIX demand in Q2 2026 came from new or returning patients.
SignificanceAcadia credits STIX for the record Q2 2026 net sales of US$125m (+30% YoY) and the guidance upgrade
AttributeTrofinetide: DAYBU® (EU)
ApprovalEuropean Commission, 24 Aug 2026, for neurobehavioural symptoms of Rett syndrome in adults and children aged 5 and over
CoverageAll 27 EU member states plus Iceland, Liechtenstein and Norway
PathNegative CHMP trend vote (Feb 2026), then negative opinion (Mar 2026), then re-examination, then positive opinion (Jun 2026), then EC approval
Next Neuren paymentUS$35m on first commercial sale. Germany launch expected early Q4 2026. No launch announcement had been located by 12 Oct 2026.
AttributeTrofinetide: Japan program
StatusAcadia-run clinical trial. Top-line results are expected Sep–Nov 2026. A regulatory submission under Orphan Drug designation is anticipated in 2027.
Next Neuren paymentUS$15m on first commercial sale

Clinical pipeline: NNZ-2591 (ercanetide), wholly owned by Neuren (ex-Rett and Fragile X)

ProgramStageKey data / statusDesignationsSource
Phelan-McDermid syndrome (PMS)Phase 3 ("Koala")Randomised, double-blind, placebo-controlled; about 160 children aged 3–12; 13-week treatment plus 52-week open-label extension. First participant dosed Feb 2026. Sites grew from 2 to 15 (US and Canada) during 2026. Over 100 families referred. 8 extension-study sites active. Program cost guided at US$80–90m. Formal top-line timing guidance to come after further enrolment milestones.Orphan Drug (US, EU), Fast Track, Rare Pediatric DiseaseH1 2026 announcement
Pitt Hopkins syndrome (PTHS)End of Phase 2Positive Phase 2 (May 2024). FDA's written feedback in early 2026 suggested a design similar to the PMS trial; Neuren considered that "not appropriate or executable" given PTHS rarity. A Type B End of Phase 2 face-to-face meeting with FDA is scheduled for late Oct 2026. An externally-led patient-focused drug development meeting is scheduled for 13 Nov 2026.Orphan Drug (US, EU), Fast Track, Rare Pediatric DiseaseH1 2026 announcement
Angelman syndrome (AS)Phase 2 completedPositive Phase 2 (Aug 2024): clinician-rated CGI-I mean 3.0 (11 of 13 children improved, p=0.0010); caregiver-rated CIC mean 3.2 (p=0.0273). Neuren has signalled priority for PMS and PTHS, where competition is lower.Orphan Drug (US, EU), Fast Track, Rare Pediatric DiseaseASX 9 Aug 2024; Angelman.org
Hypoxic-ischemic encephalopathy (HIE)Pre-INDFDA generally accepted the proposed IND-opening study and doses (Feb 2026) but requested an additional juvenile animal safety study. Neuren submitted the protocol in May 2026 but has not received feedback. IND now expected H1 2027 (previously Q4 2026).—H1 2026 announcement
Prader-Willi syndrome (PWS)Open IND (2024)Neuren held an open US IND in 2024. It is not named in the H1 2026 pipeline description, and current status was not clarified in sources reviewed.—ASX 9 Aug 2024
SYNGAP1-related disorder (SRD)Early / preclinicalAdded to the pipeline in 2025 (FY2025 results). It is not named in the H1 2026 pipeline description, and current status was not clarified in sources reviewed.—FY2025 Appendix 4E
Rett and Fragile X (NNZ-2591)Licensed to AcadiaAcadia holds worldwide rights; development status not disclosed by Neuren—Neuren company description

Financial Narrative

Income statement

Sources: FY2025 Appendix 4E; FY2024 results; FY2023 results (FNArena, Biotech Daily); FY2021–FY2023 line items from Yahoo Finance (financial statements data). FY2024 R&D and corporate costs are derived from the FY2025 Appendix 4E, which reports FY2025 R&D up A$3.4m to A$36.4m and corporate costs up A$1.5m to A$6.2m. FY2025 PBT is derived as NPAT plus tax; the company rounds it to A$39m.

EPS discrepancy: FNArena reports FY2023 EPS as A$1.236, while Biotech Daily reports A$1.2016. This likely reflects a basic versus diluted difference and is noted rather than resolved.

EBITDA: depreciation and amortisation are immaterial (net PP&E was A$31k at FY2024). EBITDA therefore approximates operating income but is not reported by the company and is left blank.

Margins (derived)

Revenue CAGR. FY2022–FY2025 three-year CAGR is about 80% (derived: 14.55 to 84.8). A five-year CAGR is not meaningful because FY2021 revenue was nil. Royalty income CAGR for FY2023–FY2025 is about 55% (derived: 26.8 to 64.6). The FY2023 base covers only about 8.5 months of sales.

Balance sheet

Sources: Moomoo/Yahoo balance-sheet data for FY2020–FY2024 cash and receivables; FY2025 Appendix 4E for FY2025 cash; FinancialFilings summary of the FY2025 Annual Report for total assets and equity. Goodwill is shown as nil because no acquisitions have been made; this is not separately confirmed from the notes.

The FY2024 receivables spike (A$157.6m) reflects Q4 2024 PRV proceeds, the sales milestone and Q4 royalty, all received in Q1 2025. Pro-forma cash at 31 Dec 2024 after these receipts and Q4 tax was A$359.4m (FY2024 results).

H1 2026 balance sheet: cash and short-term investments of A$287m; total assets of A$340.6m; no debt (H1 2026 Appendix 4D).

Working capital: Almost the entire asset base is cash, term deposits and receivables against about A$4.4m of total liabilities (FY2025). Working capital is therefore roughly equal to net assets, about A$338m (derived).

Cash flow

Sources: Q4 2023 Activity Report ("cash generated from operations ... full-year A$185 million"); FY2025 results (OCF A$125m versus A$11m used in 2024; tax payments A$54m in 2025); FY2025 Appendix 4E and H1 2025 announcement for buybacks. Capex is immaterial (PP&E is in the tens of thousands of dollars) and is shown as nil.

FY2024's negative operating cash flow is a timing effect: most FY2024 income was earned in Q4 and collected in Q1 2025.

H1 2026: buybacks of A$3.9m. First interim dividend of A$19.0m declared, paid 7 Oct 2026, so it falls in H2 2026 cash flow.

Commentary on trends, inflections and drivers

FY2021–FY2022: pre-commercial developer. Neuren lost A$7.8m in FY2021 and spent about A$9.5m on R&D, mainly the NNZ-2591 Phase 1 program and drug manufacture (H1 2022 Appendix 4D). FY2022 brought the first licence-related revenue (A$14.55m) and a small profit (A$0.18m). Cash rose only slightly to A$40.2m.

FY2023: transformation year. FDA approval and the US launch triggered three income streams at once: royalties (A$26.8m at a 10% first-tier rate), the first-commercial-sale milestone (A$59.4m), and the upfront payment for the global licence expansion (about A$146m). Revenue rose roughly 16-fold to A$231.9m. Net profit was A$157.1m after A$48.1m of tax, and cash rose more than five-fold to A$228.5m without dilution.

FY2024: record income with a shift in mix. Royalties more than doubled to A$56.2m as DAYBUE net sales grew 97% to US$348.4m. Revenue also included the first sales milestone (A$80.5m) and Neuren's share of PRV proceeds (A$76.5m). The A$7.2m net FX loss was offset by A$24m of FX translation gains in other comprehensive income. Recognition of previously unrecognised New Zealand tax losses (about A$17m) reduced tax expense. Neuren started buying back shares.

FY2025: normalisation to a royalty-only base. With no milestones, revenue fell 63% to A$84.8m and net profit fell 79% to A$30.4m. Recurring royalty income still grew 15% to A$64.6m. R&D rose to A$36.4m as Koala began. Operating cash flow was A$125m because FY2024 receivables were collected, and cash rose to A$296.1m despite A$39.6m of buybacks and A$54m of tax payments.

H1 2026: investment phase plus capital return. Royalty income rose 29% in US$ terms, but R&D almost doubled to A$27.4m, and net profit fell to A$4.9m. With royalties growing and R&D funded from the cash pile, Neuren introduced a dividend of 70–100% of the after-tax "Available Pool", defined as royalty income less corporate costs, after tax at 30%. This deliberately separates shareholder distributions from R&D spending.

Structural features to note:

  1. Revenue is US$-denominated while reporting is in A$. FX moves create translation gains and losses: an A$8.0m gain in FY2025 and an A$4.0m gain in H1 2026.

  2. The company pays Australian/NZ corporate tax, which generates franking credits for dividends.

  3. Profitability now depends on the pace of NNZ-2591 R&D rather than on revenue. As the Phase 3 program scales, reported profit could fall further even as royalties grow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue Lines

Revenue line (AUD Mn)FY2021FY2022FY2023FY2024FY2025

Royalty income (DAYBUE)

0026.856.264.6

First commercial sale milestone

0059.400

Sales milestone (US$250m threshold)

00080.50

Upfront licence fee (global expansion)

00145.700

Share of PRV sale proceeds

00076.50

Licence or milestone revenue (pre-launch)

—14.55000

Other revenue incl. finance income (derived residual)

——014.620.2

Total revenue from ordinary activities

014.55231.9227.884.8

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025

Royalty share of total revenue (%)

011.624.776.2

Royalty YoY growth, A$ (%)

——109.715.0

Total revenue YoY growth (%)

—1,494-1.8-62.8

Pre-tax margin (%)

1.388.480.346.0

Results by Segment and Revenue by Segment

MetricH1 2025H1 2026Change

Royalty income (USD Mn)

18.123.3+29%

Royalty income (AUD Mn)

28.333.2+17%

Revenue from ordinary activities (AUD Mn)

39.542.7+8%

R&D expense (AUD Mn)

14.927.4

+A$12.5m

Corporate & administration (AUD Mn)

—3.0—

Finance (interest) income (AUD Mn)

—5.6—

FX gain (AUD Mn)

—4.0—

Profit before tax (AUD Mn)

19.7——

Profit after tax (AUD Mn)

15.04.9-67%

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total revenue from ordinary activities (AUD Mn)

014.55231.9227.884.8

Royalty income (AUD Mn)

0026.856.264.6

Gross profit (AUD Mn; no cost of sales)

014.55231.9——

R&D expense (AUD Mn)

9.512.726.833.036.4

Corporate & administrative (AUD Mn)

1.93.45.94.76.2

Operating income (AUD Mn)

-11.4-1.6199.2——

Profit before tax (AUD Mn)

-7.80.18205.1183.038.9

Income tax expense (AUD Mn)

0048.140.98.5

Net profit after tax (AUD Mn)

-7.80.18157.1142.030.4

Basic EPS (AUD)

——1.2361.1110.2373

Dividends per share (AUD)

00000

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025

Operating margin (%)

-11.085.9——

Pre-tax margin (%)

1.288.480.345.9

Net margin (%)

1.267.762.335.8

R&D as % of revenue (%)

87.311.614.542.9

Effective tax rate (%)

023.422.321.9

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Cash & short-term investments (AUD Mn)

36.840.2228.5222.2296.1

Total assets (AUD Mn)

————342.9

Total equity (AUD Mn)

————338.5

Total liabilities (AUD Mn, derived)

————4.4

Short-term debt (AUD Mn)

00000

Long-term debt (AUD Mn)

00000

Net debt (AUD Mn; negative = net cash)

-36.8-40.2-228.5-222.2-296.1

Receivables (AUD Mn)

1.41.114.4157.6—

Goodwill & intangibles (AUD Mn)

00000

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (AUD Mn)

——185.0-11.0125.4

Capex (AUD Mn)

00000

Free cash flow (AUD Mn, derived)

——185.0-11.0125.4

Tax paid (AUD Mn)

————54.0

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00010.439.6

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025Basis

ROE (%)

——9.0

NPAT ÷ closing equity (derived)

ROA (%)

——8.9

NPAT ÷ closing total assets (derived)

ROIC

n/m

n/m

n/m

Invested capital is effectively nil once cash is excluded, so ROIC is not meaningful

Current ratio

High

High

Above 70x

Liabilities about A$4.4m versus mostly current assets (derived, approximate)

Debt / equity

000

No borrowings

Net debt / EBITDA

Net cash

Net cash

Net cash

FNArena shows Debt/EBITDA of 0

Interest coverage

n/m

n/m

n/m

No interest expense

Asset turnover

——0.25x

Revenue ÷ closing total assets (derived)

Cash conversion cycle

n/m

n/m

n/m

No inventory or payables cycle; royalties are received quarterly in arrears

Revenue by Region and Region Margins & Growth (%)

Region (USD Mn)FY2023FY2024FY2025

United States / North America net sales (USD Mn)

177.2348.4391.4

Europe net sales (USD Mn)

000

Japan net sales (USD Mn)

000

Global DAYBUE net sales (USD Mn)

177.2348.4391.4

YoY growth, global (%)

—96.612.3

Revenue by Region

Region (AUD Mn)FY2023FY2024FY2025

North America royalties (AUD Mn)

26.856.264.6

Ex-North America royalties (AUD Mn)

000

Revenue by Region (Quarterly)

MetricQ1 2025Q4 2025Q1 2026Q2 2026

DAYBUE net sales (USD Mn)

84.6109.6101125

Neuren royalty (USD Mn)

——10.412.9

Share Price History

DatePrice (AUD)ContextSource

30 Oct 2023

10.02

52-week low

Kalkine

28 Dec 2023

25.11

Record high (Kalkine cites A$25.95 intraday)

InvestSMART / Kalkine

3 Feb 2026

14.58

After negative CHMP trend vote (-10%)

Capital Brief

27 Feb 2026

13.44

At FY2025 results release

InvestSMART

Early Apr 2026

13.13

About -30% year to date

Motley Fool

24 Jul 2026

16.46

Post-CHMP positive opinion

InvestSMART

26 Aug 2026

22.53 then 20.67

H1 result day (-8%)

InvestSMART

27 Aug 2026

21.02—

FNArena

8 Sep 2026

20.64

Last verified price

Trading Economics

Share Price & Returns

PeriodReturnNote

1-year (to 8 Sep 2026)

About +2%

Trading Economics. Motley Fool cited a gain of over 25% for the 12 months to 26 Aug 2026; the difference reflects measurement dates around the Sep 2025 peak of about A$20. Both noted.

Valuation Snapshot

MultipleValueBasis

Market capitalisation

About A$2.61bn

Derived

Enterprise value

About A$2.32bn

Market cap less A$287m cash (30 Jun 2026)

Trailing P/E (FY2025 EPS A$0.2373)

About 87x

Derived. StockLight shows about 137x on a trailing-12-month basis.

Forward P/E (FY2026 consensus EPS 39.8c, FNArena)

About 52x

Derived

Forward P/E (Bell Potter FY2027 EPS 53.6c)

About 39x

Derived

EV/Sales (FY2025 revenue A$84.8m)

About 27x

Derived

EV/Royalty (FY2026 midpoint about A$77.7m)

About 30x

Derived

P/B (FY2025 equity A$338.5m)

About 7.7x

Derived

Analyst Ratings & Targets

BrokerRatingTarget (AUD)Key forecastsDate

Canaccord Genuity

Buy

24.76—

30 Aug 2026

Bell Potter

Positive (top pick lists, Oct 2026)

—

FY2026 DPS 33c, EPS 35.5c; FY2027 DPS 37c, EPS 53.6c

27 Aug 2026

Macquarie

Positive coverage ("could jump more than 50%")

——2026

FNArena consensus

—

25.00 (about 19% upside at A$21.02)

FY2026 EPS 39.8c

Aug 2026

Dividend History

PeriodDPS (AUD)FrankingEx-datePaymentPayout

H1 2026 interim

0.15100%

15 Sep 2026

7 Oct 2026

90% of the A$21.1m Available Pool (A$19.0m)

H2 2026 final

To be determined

Expected fully franked

——

Policy range 70–100% of the H2 Available Pool. The FY2026 pool is estimated at A$48.0–51.6m, implying an H2 pool of about A$27–30m (derived).

Capital Markets

ItemDetail

Buybacks completed

A$10.4m (2024), A$39.6m (2025), A$3.9m (H1 2026)

Credit ratings (Moody's / S&P / Fitch)

Not rated; no debt

Debt maturity profile

Not applicable (no borrowings)

Analyst Conclusions

Management guidance and consensus

FY2026 royalty income: US$53–56m (about A$75–80m at 0.70), up roughly 16–24% on FY2025's A$64.6m in A$ terms.

FY2026 Available Pool: A$48.0–51.6m. This funds the H2 dividend.

Acadia DAYBUE FY2026 net sales: US$480–510m. The 2028 target is US$700m.

Consensus: FY2026 EPS of about 39.8c (FNArena). Bell Potter forecasts EPS of 35.5c (FY2026) and 53.6c (FY2027), and DPS of 33c and 37c.

NNZ-2591: Koala top-line timing to be guided later. PTHS path to be set at the late-Oct 2026 FDA meeting. HIE IND in H1 2027.

Bull case

  1. Royalty growth reaccelerating plus new geographies. DAYBUE grew 30% YoY in Q2 2026 on STIX adoption. EU approval and a likely Japan filing add higher-rate royalties of mid-teens to low-20s percent. The pending US$35m EU first-sale milestone and the US$50m North American US$500m milestone (plausible in 2027 given 2026 guidance of US$480–510m) add about US$85m of one-off income.

  2. PMS Phase 3 optionality funded without dilution. Neuren holds A$287m of cash against a US$80–90m PMS program budget. A positive Koala result would establish the first approved PMS therapy, in a disease now estimated at 1 in 7,300 people. It would also trigger a fully owned PRV worth about US$215m on recent comps.

  3. Unusual capital return profile for a biotech. Fully franked dividends of 70–100% of the Available Pool, plus buybacks, give a valuation floor and broaden the investor base beyond specialist biotech funds.

Bear case

  1. The valuation already discounts much of the upside. At about 87x trailing earnings, about 30x EV/FY2026 royalty and 7.7x book, the market implies substantial NNZ-2591 success. A negative Koala outcome would leave a single-product royalty stream with a finite exclusivity horizon (statutory NCE about 2028; orphan exclusivity about 2030).

  2. Effect-size and durability questions for trofinetide. The CHMP's initial refusal cited limited treatment effect. EU payers may restrict price and access, and gene therapies in Rett pose a long-term substitution risk.

  3. Execution and regulatory friction in the pipeline. FDA's PTHS feedback, the HIE IND delay and no formal Koala top-line guidance suggest timelines could extend. R&D could keep rising (H1 2026 R&D was A$27.4m, up 84%), compressing reported profit and the payout base.

Catalysts and monitorables (next 12 months)

Expected timingCatalystWhy it matters
Sep–Nov 2026Japan trofinetide top-line resultsGates a 2027 submission, the US$15m first-sale milestone and up to US$110m of sales milestones
Early Q4 2026Germany launch of DAYBUUS$35m milestone; first EU royalties
Late Oct 2026FDA Type B meeting (PTHS)Feasibility and design of a PTHS registrational path
Nov 2026Acadia Q3 2026 resultsRun-rate toward the US$480–510m guidance
13 Nov 2026PTHS patient-focused drug development meeting with FDAPatient-voice evidence base
Feb 2027FY2026 results and final dividendConfirms payout ratio and 2027 royalty guidance
H1 2027HIE IND submission and FDA meetingFourth indication
2,027Koala enrolment milestones and top-line guidancePrimary value driver
2,027Japan regulatory submissionEx-US expansion

Analyst verdict

Neuren has completed a rare transition in Australian biotech: from a cash-consuming developer to a profitable, debt-free, dividend-paying royalty company, without raising equity at the point of commercial success. The trofinetide economics are now proven. DAYBUE generated US$391m of net sales in 2025 and is guided to US$480–510m in 2026. Neuren's royalty grew 29% in US$ terms in H1 2026, and the August EU approval opens higher-rate royalties plus a near-term US$35m milestone. The balance sheet of A$287m cash and no debt fully funds a US$80–90m PMS Phase 3 while supporting a payout of 70–100% of royalty-based earnings.

The investment debate has moved from "will trofinetide work commercially?" to "what is NNZ-2591 worth?" At about A$2.6bn market capitalisation and about A$2.3bn enterprise value, the market values Neuren at roughly 30x 2026 royalty income. That multiple only makes sense if a meaningful share of value is attributed to NNZ-2591, the PRV option and the remaining trofinetide milestones. The PMS Phase 3 is therefore the dominant determinant of long-term returns. It has encouraging Phase 2 consistency across three syndromes, FDA alignment on design, and no late-stage competitor. However, the absence of top-line timing guidance and the regulatory friction in PTHS and HIE are reminders that ultra-rare development rarely runs to schedule.

On balance, Neuren is a high-quality, self-funded rare-disease franchise with an asymmetric pipeline option and a growing income floor. Over the next 12 months the key watchpoints are:

  • Japan top-line results;

  • Germany launch execution;

  • the late-October FDA meeting on PTHS;

  • Acadia's progress toward the US$500m North American threshold;

  • any formal guidance on when Koala will read out.

Our stance is constructive with a valuation caveat. Risk/reward looks best on drawdowns linked to sentiment rather than fundamentals, as seen in February–April 2026.


Sources (primary): Neuren ASX announcements: 31 Jan 2024; 24 Apr 2024; 27 May 2024; 9 Aug 2024; 7 Oct 2024; 7 Nov 2024; 28 Feb 2025; 3 Apr 2025 (2024 Annual Report); 27 May 2025; 27 Aug 2025; 3 Feb 2026; 27 Feb 2026 (Appendix 4E and results); 3 Mar 2026; 7 May 2026; 27 May 2026; 5 Aug 2026; 26 Aug 2026 (Appendix 4D and dividend announcement). Acadia Pharmaceuticals Form 8-K exhibits 99.1 (FY2024, Q1 2025, FY2025).

Sources (secondary, flagged where used): FNArena; Motley Fool Australia; InvestSMART; Market Index; Trading Economics; StockLight; FinancialFilings; Biotech Daily; Biotech Dispatch; Capital Brief; Quartr; Kalkine; Yahoo Finance; Barchart; Moomoo; MarketScreener; StockWireX; FilingReader; Angelman.org.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundSource

Jonathan (Jon) Pilcher

CEO & Managing Director

Long-serving Neuren executive, previously CFO. Succeeded Dr Richard Treagus as CEO after 2020; Managing Director from 14 Jun 2021 per InvestSMART. Morningstar records an association with the company since Aug 2013.

InvestSMART; Morningstar via Motley Fool; FNArena

Lauren Frazer

CFO & Company Secretary

In role since Aug 2020. Over 25 years' experience in ASX- and Nasdaq-listed companies (business development, capital raising, IR, governance). Has served on boards and the Children's Medical Research Institute IP sub-committee.

Morningstar via Motley Fool

Gerry (He) Zhao

Chief Business Officer

Previously VP Corporate Development; CBO from about 2024 (MarketScreener: IR contact from 1 Jul 2024). Presented the H1 2026 results. Historical registers show a holding of 405,000 shares (0.32%).

MarketScreener; Quartr; Motley Fool

Dr Liza Squires

Chief Medical Officer

Leads clinical development of NNZ-2591

InvestSMART

Clive Blower

Chief Operations Officer

Operations and manufacturing oversight

InvestSMART

Daryl Dekarske

Chief Regulatory Officer

Regulatory strategy (FDA, EMA)

InvestSMART

Dr Larry Glass

Chief Science Officer

Science and preclinical

InvestSMART

Nancy Jones

VP Clinical Development

Quoted in the PTHS Phase 2 release (May 2024)

ASX 27 May 2024

Board of Directors

NameRoleAppointedBackgroundIndependence

Patrick Davies

Non-Executive Chairman

1 Jul 2018

Former CEO of EBOS Group (and previously Symbion). During his ten-year tenure, group enterprise value grew from about A$450m to over A$3.1bn (+20% CAGR).

Independent (non-executive)

Jon Pilcher

CEO & Managing Director

MD from 14 Jun 2021

See above

Executive

Dianne Angus

Non-Executive Director

Jul 2018

Executive and director experience in biotech, biopharma, medical devices, agritech and healthcare; global industry partnerships

Independent (non-executive)

Dr Jenny Harry

Non-Executive Director

Jul 2018

About 20 years in biotech/biopharma executive management; CEO/MD experience from start-up to commercialisation

Independent (non-executive)

Joseph (Joe) Basile

Non-Executive Director

Mar 2023

Over 30 years in pharma; former Group CFO of iNova Pharmaceuticals (Singapore); senior finance and commercial roles at Novartis (Australia/Asia)

Independent (non-executive)

Board & Management Changes

DateChange

Mar 2023

Joe Basile joined the board

c.2024

Gerry Zhao promoted to Chief Business Officer

2024–2025

Leadership expanded with Chief Regulatory, Operations and Science officers as Neuren moved "from Phase 2 development to Phase 3 development" (2025 AGM address)

Major Shareholders

HolderStakeDate / source

Milford Asset Management

About 5.14% (largest holder at the time)

FY2023 data (Kalkine, 2024).

Cameron Richard Pty Ltd

About 3.23%

FY2023 data (Kalkine)

Top 10 shareholders combined

About 22.7%

FY2023 data (Kalkine)

Current top-10 holders and substantial holder notices

—

See the 2025 Annual Report shareholder information

Competitive Landscape

Competitors by Segment

IndicationCompetitorAsset / modalityStage (as known)Positioning vs Neuren

Rett syndrome

Taysha Gene Therapies

TSHA-102 (AAV9 MECP2 gene therapy)

Pivotal-stage clinical development

Potential one-time therapy; could compete with or complement chronic trofinetide

Rett syndrome

Neurogene

NGN-401 (gene therapy)

Clinical

Same as above

Rett syndrome

Anavex Life Sciences

Blarcamesine (sigma-1 agonist)

Mixed clinical results; not approved

Small-molecule alternative; lower probability

Phelan-McDermid syndrome

Jaguar Gene Therapy

SHANK3 gene therapy (JAG201)

Early clinical

Neuren is materially ahead (only Phase 3 in PMS)

Angelman syndrome

Ultragenyx

GTX-102 (antisense oligonucleotide, intrathecal)

Phase 3

Disease-modifying ASO, ahead of NNZ-2591

Angelman syndrome

Ionis Pharmaceuticals

ION582 (ASO)

Phase 3

Same as above

Angelman syndrome

Roche

Rugonersen (ASO)

Clinical

Big-pharma competitor

Prader-Willi syndrome

Soleno Therapeutics

DCCR (diazoxide choline, VYKAT XR)

Approved in US (2025)

Established hyperphagia therapy

Prader-Willi syndrome

Harmony Biosciences; Aardvark Therapeutics

Pitolisant; ARD-101

Clinical

Crowded field (Neuren cited "other trials available" for PWS families in 2024)

Fragile X (Acadia-licensed)

Shionogi / Tetra

Zatolmilast (PDE4D inhibitor)

Late clinical

Relevant to Acadia's NNZ-2591 and trofinetide Fragile X options

Pitt Hopkins syndrome

None identified at late stage

——

Neuren cites a lack of competing therapies

HIE

No approved drug; therapeutic hypothermia is standard of care

——

Large unmet need; early stage for Neuren

Peer Comparison FY2025

MetricNeuren (FY2025)Acadia Pharmaceuticals (FY2025)

Revenue

A$84.8m

US$1.07bn (GAAP)

Revenue growth

-63% total; +15% royalty

+12%

Net margin

35.8%—

R&D intensity

42.9% of revenue

—

Business model

Royalty plus wholly owned pipeline

Commercial (NUPLAZID, DAYBUE)

Company Snapshot

2001

Founded

Hawthorn East, Australia

Headquarters

SWOT Analysis

Strengths

  • Profitable, debt-free balance sheet. Cash and short-term investments of A$287m at 30 Jun 2026, no borrowings, and total liabilities of only about A$4.4m at FY2025.
  • Growing recurring royalty. FY2025 royalty of A$64.6m (+15%). H1 2026 royalty of US$23.3m (+29% in US$). FY2026 guidance of US$53–56m.
  • Approved first-in-class asset. Trofinetide is the only approved Rett therapy in the US, EU, Canada and Israel.
  • Strong cash generation. FY2025 operating cash flow of A$125.4m. Cumulative licence income of about A$543m since launch (H1 2026).
  • Phase 3 leadership in PMS. Koala is the first-ever PMS Phase 3; FDA-aligned design; 15 sites active.
  • Shareholder returns. First fully franked dividend (15c); A$50m buyback completed at A$12.27 against a share price of about A$20 in Sep 2026.

Weaknesses

  • Total dependence on one licensee and one product. 100% of operating revenue comes from Acadia/DAYBUE.
  • Lumpy reported earnings. NPAT fell from A$142.0m (FY2024) to A$30.4m (FY2025) and A$4.9m (H1 2026) as milestones ended and R&D rose.
  • No commercial control. Pricing, access and launch timing sit with Acadia, including the STIX rollout and the EU launch sequence.
  • Modest clinical effect size for trofinetide, cited by the CHMP in its initial refusal (Mar 2026).
  • FX exposure. Revenue is in US$ and reporting in A$. FX effects swing results: an A$7.2m net FX loss in FY2024, then an A$8.0m gain in FY2025.
  • Limited disclosure depth. Headcount, patent counts and detailed remuneration are not easily accessible.

Opportunities

  • EU launch. US$35m first-sale milestone, up to US$170m of sales milestones and royalties of mid-teens to low-20s percent.
  • Japan. Top-line results due Sep–Nov 2026; US$15m first-sale milestone; up to US$110m of sales milestones.
  • Next North American milestone. US$50m when North American net sales exceed US$500m in a calendar year. 2026 global guidance is US$480–510m, and the 2028 target is US$700m.
  • PRV monetisation. A voucher on approval of NNZ-2591 in PMS, PTHS or AS would be 100% Neuren-owned. Recent sale value was US$215m (Jul 2026).
  • NNZ-2591 multi-indication expansion into PTHS, AS and HIE.
  • Partnering NNZ-2591 ex-US, which would bring non-dilutive capital. This is speculative and not announced.

Threats

  • Koala Phase 3 failure, which would remove most of the pipeline value.
  • Gene therapies in Rett (Taysha, Neurogene) eroding DAYBUE's long-term market.
  • Regulatory friction. FDA's PTHS design feedback was deemed "not appropriate or executable" by Neuren. The HIE IND has slipped to H1 2027.
  • EU reimbursement. Given the CHMP's initial scepticism on effect size, health-technology-assessment bodies may constrain pricing and uptake.
  • Exclusivity horizon. Statutory US NCE exclusivity nominally ends around Mar 2028, so durability depends on patents and orphan exclusivity.
  • Partner risk. Strategic changes at Acadia (resource allocation, M&A) could affect DAYBUE investment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 2025Received A$76.5m PRV proceeds, A$80.5m sales milestone and Q4 2024 royalty; paid Q4 2024 taxPro-forma cash of A$359m; cash of A$341m at 31 Mar 2025 (2025 AGM)
H1 2025Completed A$50m buyback at an average of A$12.27First large capital return
H1 2025FDA Fast Track for NNZ-2591 in PTHSRegulatory momentum
H1 2025HIE added as an NNZ-2591 indicationExpands addressable market beyond genetic syndromes
27 May 20252025 AGM. Chair highlighted record FY2024 and the shift to Phase 3 capability.Strategy reaffirmed
22 Jul 2025CEO converted 1.5m loan-funded shares at A$1.84Insider alignment
27 Aug 2025H1 2025 results: NPAT A$15.0m (up from A$8.0m); cash A$300m; Acadia 2025 guidance US$380–405mRoyalty growth intact
8 Sep 2025CEO sold 398,207 shares at A$20.00Insider selling near the share price peak
2025Koala Phase 3 initiated; Fast Track for PMS; SYNGAP1 addedPipeline expansion
Late 2025Neuren announced a new on-market buyback (Motley Fool coverage)Continued capital management
Jan 2026Q4 2025 royalty A$20m (+7% YoY, +21% QoQ); record Q4 DAYBUE net sales of US$110mStrong exit rate
3 Feb 2026Negative CHMP trend vote on trofinetide EU application; shares fell about 10% to A$14.58Major setback to the EU thesis
Feb 2026First Koala participant dosed after a 4-week screening periodPhase 3 under way
Feb 2026FDA written feedback on the HIE IND plan requested a juvenile animal studyTimeline risk
Feb 2026US Congress reauthorised the PRV program to 30 Sep 2029Restores voucher optionality for NNZ-2591
25–27 Feb 2026Acadia FY2025: DAYBUE US$391.4m (+12%); 2026 guidance US$460–490m. Neuren FY2025: royalty A$64.6m, NPAT A$30.4m, cash A$296.1m.Recurring base established
3 Mar 2026CHMP formally adopted its negative opinion, citing limited magnitude of the 12-week effect and study design issues. Acadia requested re-examination.EU path prolonged
Q1 2026DAYBUE STIX limited launch (over 250 prescriptions; about 30% new or returning patients)New growth driver
Early Apr 2026STIX broad US rollout. Neuren shares rebounded about 7% to A$13.13 after falling about 30% year to date.Sentiment trough
24 Apr 20262025 Annual Report releasedStatutory filing
7 May 2026Acadia Q1 2026: DAYBUE US$101m (+20%); Neuren royalty US$10.4m (+23%); Japan trial acceleratedGrowth reacceleration
27 May 20262026 AGM. Cumulative licence income since launch A$525m.Shareholder communication
Late Jun 2026Positive CHMP opinion on re-examination (announced 29 Jun 2026)EU setback reversed
24 Jul 2026Neuren Presenting Sponsor at the PMSF Family ConferenceKoala enrolment support
Jul 2026Third-party PRV sale for US$215m (industry benchmark cited by Neuren)Valuation reference for NNZ-2591 vouchers
5 Aug 2026Acadia Q2 2026: DAYBUE US$125m (+30% YoY, +24% QoQ); guidance raised to US$480–510m; Neuren royalty US$12.9m (+34%)Guidance upgrade; share price rally
24 Aug 2026European Commission approved DAYBUUnlocks US$35m first-sale milestone and EU royalties
26 Aug 2026H1 2026 results: NPAT A$4.9m; cash A$287m; first dividend of 15c fully franked. Shares fell about 8% intraday.Capital return policy launched
27–30 Aug 2026Bell Potter noted an earnings beat on lower-than-forecast opex. Canaccord kept Buy with a A$24.76 target.Broker support
15–16 Sep 2026Ex-dividend and record dates—
7 Oct 2026Interim dividend paid (A$19.0m)First distribution in company history
Pending (Sep–Nov 2026)Japan trofinetide top-line results. No announcement located as of 12 Oct 2026.Key near-term catalyst
Pending (early Q4 2026)Germany commercial launch and US$35m milestone. No announcement located as of 12 Oct 2026.Key near-term catalyst
Pending (late Oct 2026)FDA Type B meeting for PTHSDetermines the PTHS path

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

10 charts
Income Statement: Revenue & Gross Profit: Total revenue from ordinary activities rose from AUD 0 Mn in FY2021 to AUD 84.8 Mn in FY2025.
Neuren Pharmaceuticals Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2021FY2022FY2023FY2024FY2025
Total revenue from ordinary activities014.6231.9227.884.8
Gross profit014.6231.9——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.